Breast cancer prevention

British Journal of General Practice

Volumn 52, Issue 485, 2002, Pages 972-973

  Mokbel, Kefah ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTIESTROGEN; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; GOSERELIN; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D DERIVATIVE;

ANGIOGENESIS; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COGNITION; DRUG TOLERABILITY; EDITORIAL; ENDOMETRIUM CANCER; GENE THERAPY; GYNECOLOGIC CANCER; HIGH RISK POPULATION; HUMAN; MASTECTOMY; META ANALYSIS; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OVARIECTOMY; PREMENOPAUSE; PROPHYLAXIS; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY; SIDE EFFECT;

ALCOHOL DRINKING; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; CYCLOOXYGENASE 2; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; ISOENZYMES; LIFE STYLE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS; UP-REGULATION;

EID: 0036898914     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Mokbel K, Leris C. The prevention of breast cancer: An overview. Curr Med Res Opin 2001; 16: 252-257.
2. Collaborative Group of Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Further results. Contraception 1996; 54: 1S-106S.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
6. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-97.
7. Cuzick J. Update on new studies in Europe. Eur J Cancer 2002; 38: 544 (Abstract 20).
8. Rebbeck TR, Levin Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-1479.
9. Cummings SR, Eckert S, Krueger, et al. The effect of raloxifene on the risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA 1999; 281: 2189-2197.
10. Arimidex, tamoxifen alone or in combination trial. Anastrozole alone or incombination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
11. Khuder SA, Mutgi AB. Breast cancer and NSAID use: A meta-analysis. Br J Cancer 2001; 84: 1188-1192.
12. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
13. Kauff ND, Satagopan JM, Robson MF, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.